Faruqi & Faruqi, LLP Reminds SLNO Investors of Class Action Deadline

Important Notice to SLNO Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, has announced that it is currently evaluating possible claims against Soleno Therapeutics, Inc. (NASDAQ: SLNO). Investors who purchased shares between March 26, 2025, and November 4, 2025, are especially urged to pay close attention as the deadline to seek a lead plaintiff role in a federal securities class action is set for May 5, 2026.

Background on Soleno Therapeutics

Soleno Therapeutics, a biotechnology company, focuses on developing therapies for rare diseases, notably treatments for Prader-Willi Syndrome (PWS). The company has faced scrutiny after reports highlighted potential safety issues related to its primary drug candidate, DCCR. Key allegations against Soleno suggest that the company downplayed significant safety concerns during its Phase 3 clinical trials, which could have serious implications for patient safety and commercial viability.

Allegations and Stock Performance

The allegations stem from a report published on August 15, 2025, by Scorpion Capital LLC, which raised serious doubts regarding the safety and efficacy of DCCR. Following this report, Soleno's stock price drastically decreased, falling nearly 12% over two trading days. The negative momentum continued after Soleno reported on September 10, 2025, that a patient died while taking DCCR, which led to an additional 19% drop in stock value.

Furthermore, the company disclosed in its financial results on November 4, 2025, that the aforementioned report impeded DCCR’s market launch and created growing concerns within the PWS community. This resulted in a staggering 27% decline in stock value on November 5, 2025.

Importance of Actively Participating

Faruqi & Faruqi, LLP emphasizes the importance of participation in the class action for investors who may have faced financial losses amid issues surrounding Soleno's disclosures. Investors are encouraged to contact Faruqi & Faruqi’s securities litigation partner, James (Josh) Wilson, directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to explore their legal options.

How to File a Claim

To be considered as a lead plaintiff, interested parties must act before the approaching deadline. The lead plaintiff role is critical as it involves directing the litigation on behalf of the class members and can influence the outcome of the case. However, interested investors can choose to remain absent from the lead plaintiff role without compromising their rights to participate in any recovery settlements.

Potential whistleblowers, former employees, or anyone with pertinent information regarding Soleno's conduct are also encouraged to come forward and contact Faruqi & Faruqi for guidance.

With the ever-increasing complexity of securities litigation, staying informed is vital. Investors should not hesitate to seek advice and act upon it before the necessary deadlines.

Conclusion

The impending May 5, 2026, deadline stands as a significant milestone in the ongoing developments regarding Soleno Therapeutics. Those impacted should not miss this opportunity to voice their concerns and pursue justice for the alleged misconduct by the company. For additional information, visit Faruqi & Faruqi’s website or follow Faruqi & Faruqi on social media.